MonicaGrazziuttiMD

Infectious Disease • Little Rock, AR

Assistant Professor, Internal Medicine, University of Arkansas COM

Join to view full profile

Dr. Grazziutti is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Grazziutti's full profile

Already have an account?

Office
UAMS Medical Center
449 Jack Stephens Drive Winthrop P. Rockefeller Cancer Institute, Sixth Floor
Little Rock, AR 72205
Phone+1 501-296-1200

Education & Training

University of Texas Health Science Center at HoustonFellowship, Infectious Disease, 1994 - 1997
Universidad Nacional de Rosario Faculty of MedicineClass of 1982

Certifications & Licensure

AR State Medical License 2006 - 2025
American Board of Internal Medicine Internal Medicine

Clinical Trials

Therapeutic Research in Multiple Myeloma Start of enrollment: 2003 Aug 01
Completed
UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma Start of enrollment: 2008 Jul 01
Active, not recruiting
Phase 3
Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy Start of enrollment: 2009 Mar 01
Active, not recruiting
Phase 2
UARK 2009-09 Myeloma Cure Project: Prospective Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple Myeloma Start of enrollment: 2010 Apr 01
Completed
Phase 3
UARK 2013-05 A Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple Myeloma Start of enrollment: 2013 Apr 01
Completed
Phase 2
Observational Study Evaluating the Potential Impact of Procalcitonin Testing on Care of Stemcell Transplant Recipients Start of enrollment: 2013 Oct 01
Completed
UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib Start of enrollment: 2015 Mar 01
Withdrawn
Phase 2
UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus Start of enrollment: 2015 Mar 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

30 citations
Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease
Meera Mohan, Amy Buros, Pankaj Mathur, Neriman Gokden, Manisha Singh
American Journal of Hematology. 2017-08-01
21 citations
The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype
Carolina Schinke, Antje Hoering, Hongwei Wang, Victoria Carlton, Sharmilan Thanandrarajan
Haematologica. 2017-08-01
11 citations
Adverse metaphase cytogenetics can be overcome by adding bortezomib and thalidomide to fractionated melphalan transplants
Yogesh Jethava, Alan Mitchell, Joshua Epstein, Maurizio Zangari, Shmuel Yaccoby
Clinical Cancer Research. 2017-06-01